Biomarkers are likely to play an increasing role in all stages of drug development. Regulatory agencies in the US and Europe are working to develop new guidelines and encourage collaboration; regulators and industry are participating in large public-private partnerships that will aid the development of these biomarkers. High-throughput approaches and new imaging and diagnostic modalities can provide many candidate biomarkers; the challenge will be to identify the most promising biomarkers and the most efficient way to progress them from discovery into the clinic. Biomarkers may hold the key to increasing the productivity of drug development and may provide more precise medicine. However, the challenge will be to ensure that this care is developed in a rapid, cost-effective way.
|Number of pages||4|
|State||Published - Jul 1 2009|